{
    "nct_id": "NCT04067726",
    "official_title": "Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)",
    "inclusion_criteria": "* Female.\n* Premenopausal (when menopausal status is uncertain, the investigators will measure follicle-stimulating hormone and estradiol to ascertain that a partcipant is premenopausal)\n* At least 40 years of age.\n* Dense breasts on routine mammogram (BI-RADS Category C and D)\n* Able to understand and willing to sign an IRB-approved written informed consent document.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 40 Years",
    "exclusion_criteria": "* History of breast or any other invasive cancer except for DCIS (ductal carcinoma in situ) who received only lumpectomy, LCIS (lobular carcinoma in situ), atypical hyperplasia, non-melanoma skin cancer, carcinoma in situ of the cervix.\n* Current use of tamoxifen, aromatase inhibitors, or bisphosphonates, or RANKL inhibitors\n* Concurrent participation in another cancer chemoprevention trial (unless no longer receiving the intervention).\n* Pregnant, lactating, or planning to get pregnant while the trial is ongoing.\n* Recent history of invasive dental procedure (e.g. tooth extraction, dental implant, oral surgery).\n* Unhealed and/or planned dental/oral surgery.\n* History of osteonecrosis/osteomyelitis of the jaw.\n* History of osteoporosis or severe osteopenia.",
    "miscellaneous_criteria": ""
}